Biomarin Pharmaceutical (BMRN) closed at $61.43 on November 18, 2026, up 5.0% from the previous close, on volume of 2,812,258 shares (30-day average 2,348,223).
Data as of November 18, 2026.
18-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Seagull With Call Spread | 15-Jan-2750 P : 57.5 C : 65 C | 3,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
H.C. Wainwright Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
TipRanks (Mon, 16-Nov 12:35 PM ET)
BioMarin Earnings Call Highlights Growth Despite Guidance Cut
TipRanks (Sat, 14-Nov 9:45 PM ET)
BioMarin Highlights Three November Investor Presentations, With Webcasts Hosted on Its IR Site
Market Chameleon (Wed, 4-Nov 4:43 AM ET)
BioMarin to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 4-Nov 9:00 AM ET)
BioMarin Reports Third Quarter 2026 Financial and Operating Results
PRNewswire (Mon, 2-Nov 4:03 PM ET)
PRNewswire (Thu, 29-Oct 8:46 AM ET)
PRNewswire (Mon, 26-Oct 9:01 AM ET)
PRNewswire (Fri, 9-Oct 9:05 AM ET)
BioMarin Appoints Cara Bauer as Chief People Officer
PRNewswire (Mon, 5-Oct 4:05 PM ET)
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Biomarin Pharmaceutical trades on the NASDAQ stock market under the symbol BMRN.
As of November 18, 2026, BMRN stock price climbed to $61.43 with 2,812,258 million shares trading.
BMRN has a beta of 0.38, meaning it tends to be less sensitive to market movements. BMRN has a correlation of 0.02 to the broad based SPY ETF.
BMRN has a market cap of $11.87 billion. This is considered a Large Cap stock.
Last quarter Biomarin Pharmaceutical reported $1 billion in Revenue and $.23 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.38.
In the last 3 years, BMRN traded as high as $99.56 and as low as $49.26.
The top ETF exchange traded funds that BMRN belongs to (by Net Assets): IJH, VTI, VB, VBK, XBI.
BMRN has outperformed the market in the last year with a price return of +12.8% while the SPY ETF gained +10.8%. However, in the short term, BMRN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -7.8% vs -5.3% return in SPY. But in the last 2 weeks, BMRN shares have fared better than the market returning +10.4% compared to SPY -3.2%.
BMRN support price is $57.40 and resistance is $59.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMRN shares will trade within this expected range on the day.